Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital

125 million dollars is being waged in the war against diabetes, and this time it’s being sent to a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease: Provention Bio. They are looking to intervene by researching, developing, and bringing medicines to market that have the potential to help patients that would have otherwise robbed them of their full lifetime of potential. So far, they have deployed multiple candidates in conjunction with other organizations to combat these conditions. The best candidate? That would be Teplizumab.